Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
HALO SEC Filing Email Alerts Service
| Company Name: |
Halozyme Therapeutics Inc |
| Stock buyback: |
HALO buyback |
| Website: |
www.halozyme.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding HALO: |
58 |
| Total Market Value Held by ETFs: |
$1.06B |
| Total Market Capitalization: |
$4.96B |
| % of Market Cap. Held by ETFs: |
21.28% |
|
|
April 28, 2024 • 9:44 PM Eastern
Strong Buy (3.60 out of 4)
63rd percentile
|
|
Free HALO Email Alerts:
